Currently, due to the better preventive effect of CGRP antibodies and the cyclical nature of migraine attacks, German and European guidelines recommend that migraine patients undergo a treatment break after 9–12 months of CGRP antibody therapy (Diener et al., 2020). This evidence concerns the gene CALCA and migraine disorder.